Brains Bioceutical Corp. Completes A Usd $31.9 Million Capital Raise With Lead Investor Dsm Venturing
Brains Bioceutical Corp. Completes A Usd $31.9 Million Capital Raise With Lead Investor Dsm Venturing
06/16/21, 9:00 AM
Location
vancouverMoney raised
$31.9 million
Brains Bioceutical Corp. (“Brains” or the “Company”) is pleased to announce the completion of a USD $31.9 million capital raise with DSM Venturing and existing Brains shareholders. DSM Venturing, who acted as lead investor in this round, is the corporate venture arm of Royal DSM (“DSM”), a global, purpose led science-based company active in health, nutrition and sustainable living. This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector
Company Info
Location
vancouver, washington, united states
Additional Info
Brains Bioceutical Corp. is a leader in EU-GMP-certified production of naturally sourced active pharmaceutical ingredients (APIs) for the pharmaceutical and nutraceutical industries. Brains Bioceutical is one of the only natural plant-based cannabinoid active pharmaceutical ingredient (API) manufacturers in commercial production today and is involved in academic and clinical trials across the globe. Brains’ Senior Management Team is comprised of a rare hybrid of pharmaceutical and consumer goods executives-having held C-suite and other senior positions with companies such as GW Pharma, Merck, Danone, Earthbound Farms, International Herbs, Cascadia Specialties and The Royal Navy. Brains' wholly owned subsidiary in the UK, BSPG Laboratories, is one of only a few companies that has the commercial capability and EU-GMDP certification to produce CBD API.